Medpace reports Q4/FY24 earnings (no specifics shown) and boosts buyback by $600M

Medpace Holdings, Inc.

Issued press release for Q4 and FY2024 results; no financial figures included in filing.
Board approved $600 million increase to existing stock repurchase program.
Repurchases may be made in open market, private deals, or via Rule 10b5-1 plan.
Program can be discontinued or amended at any time without notice.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.